AeroVironment lands $405M Middle East order for LOCUST X3 laser defense
As seen on the 24/7 Wall St. homepage on November 11, 2026.
A single $405 million export order moves AeroVironment's laser line from demo hardware to a funded foreign program, the first real proof that counter-drone energy weapons sell at scale.
AeroVironment $AVAV secures a $405M international order for LOCUST X3 laser defense systems in the Middle East. The lasers are designed to stop small and midsize drones at a lower cost than missile interceptors, with firing capacity limited mainly by power and cooling. https://t.co/keXHbOeEL1
- Replies3
- Reposts2
- Likes27
Continue ReadingShow less
AeroVironment has secured a $405 million international order for its LOCUST X3 laser defense systems, with the customer located in the Middle East. That price tag signals a foreign government committing real procurement dollars to directed-energy counter-drone technology rather than treating it as an experimental program.
The LOCUST X3 is designed to intercept small and midsize drones at a lower cost per engagement than conventional missile interceptors. That cost advantage is the core commercial argument for laser-based systems, and a funded order of this size is the clearest evidence yet that at least one foreign buyer finds it compelling enough to act on at scale.
Sponsored
The practical ceiling on how often the system can fire is set by available power and cooling capacity rather than by ammunition, which changes the economics of sustained air defense operations considerably. For a buyer facing repeated low-cost drone threats, that dynamic makes energy weapons an attractive alternative to stockpiling interceptor missiles.
For AeroVironment, this order moves the LOCUST X3 from demonstration hardware into a funded, fielded foreign program. That transition matters to investors because it suggests the laser product line has cleared the highest hurdle in defense sales: a paying sovereign customer willing to deploy the technology in an active threat environment.
Mentioned: AVAV